Skip to main content

Perceptive Advisors — Portfolio, Page 6

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

224
Companies
$24.4B
Total invested
$125.0M
Avg. check
19
Industries
Biotechnology 19Health Care 16Therapeutics 11Medical 10Biopharma 5Pharmaceutical 5+13 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 121144 of 224
Imperative Care
March 2026

Imperative Care is singularly dedicated to finding meaningful answers to unsolved problems in stroke.

Health Care · Campbell$100.0M Convertible Note
Alto Neuroscience
March 2026

Alto Neuroscience is a clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform.

Artificial Intelligence (AI) · Los Altos$120.0M Post Ipo Equity
Outlook Therapeutics
March 2026

Outlook Therapeutics is a biopharmaceutical company that develops ophthalmic formulations.

Biopharma · Iselin$18.4M Post Ipo Debt
Solid Biosciences
March 2026

Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.

Biotechnology · Charlestown$240.0M Post Ipo Equity
Beam Therapeutics
February 2026

Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.

Biotechnology · Cambridge$100.0M Post Ipo Debt
Talkiatry
February 2026

Talkiatry provides virtual mental healthcare services covered by insurance, connecting patients with licensed psychiatrists.

Health Care · New York$210.0M Series D
Xilio Therapeutics
February 2026

Xilio Therapeutics is a biotechnology company that develops tumor-activated immuno-oncology therapies.

Biopharma · Waltham$40.0M Post Ipo Equity
Nautilus Biotechnology
January 2026

Nautilus Biotechnology is a life sciences company that develops a platform for analyzing and quantifying the human proteome.

Biotechnology · San Carlos$1.6M Grant
Yarrow
December 2025

Yarrow is developing a first-in-class antibody targeting TSHR for the treatment of Graves’ disease and thyroid eye disease.

Business Intelligence · New York$200.0M Series Unknown
Contineum Therapeutics
December 2025

Contineum Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases.

Biotechnology · San Diego$99.2M Post Ipo Equity
Crescent Biopharma
December 2025

Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines.

Biotechnology · Rockville$185.0M Post Ipo Equity
Hyperfine
November 2025

Hyperfine makes MRI accessible to every patient regardless of income or resources.

Computer · Guilford$3.7M Grant
TELA Bio
November 2025

TELA Bio is a life science company that specializes in soft tissue reconstruction.

Biotechnology · Malvern$60.0M Post Ipo Debt
Cogent Biosciences
November 2025

Cogent Biosciences is a biotechnology company that develops therapies for solid cancer tumors.

Biotechnology · Waltham$200.0M Post Ipo Debt
4D Molecular Therapeutics
November 2025

4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.

Biotechnology · Emeryville$100.0M Post Ipo Equity
Nurix Therapeutics
October 2025

Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.

Biotechnology · San Francisco$250.0M Post Ipo Equity
Rapt Therapeutics
October 2025

Rapt is focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer.

Biotechnology · South San Francisco$250.0M Post Ipo Equity
Kardigan
October 2025

Kardigan develops personalized medicines using AI and data to target and treat the root causes of cardiovascular diseases.

Artificial Intelligence (AI) · South San Francisco$254.0M Series B
Spyre Therapeutics
October 2025

Spyre Therapeutics is a biotechnology business that is developing a strong pipeline of antibody therapies.

Biotechnology · Sunrise$275.0M Post Ipo Equity
Confo Therapeutics
October 2025

Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need.

Biotechnology · Brussels$1.2M Grant
TORL BioTherapeutics
October 2025

TORL BioTherapeutics is a clinical-stage biopharmaceutical business.

Biopharma · Culver City$96.0M Series C
Affinia Therapeutics
October 2025

Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with rare and prevalent diseases.

Biotechnology · Waltham$40.0M Series C
Cidara Therapeutics
October 2025

Cidara Therapeutics develops targeted immunotherapies aimed at improving treatment outcomes for patients with serious diseases.

Biotechnology · San Diego$339.0M Grant
Pepgen
September 2025

PepGen is empowering nucleic acid therapeutics to go the distance.

Biotechnology · Oxford$115.0M Post Ipo Equity

Where Perceptive Advisors invests

Biotechnology19
Health Care16
Therapeutics11
Medical10
Biopharma5
Pharmaceutical5

About Perceptive Advisors's portfolio

How many companies has Perceptive Advisors invested in?

Perceptive Advisors has invested in 224 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Perceptive Advisors invest in?

Perceptive Advisors's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Biopharma. The firm invests across 19 different industry categories.

What is Perceptive Advisors's largest investment?

Among tracked funding rounds, Cidara Therapeutics received $339.0M in a Grant round. Perceptive Advisors's total known invested capital is $24.4B.

What is the average investment size for Perceptive Advisors?

Perceptive Advisors's average investment size is $125.0M across its portfolio of 224 companies.

What are Perceptive Advisors's most recent investments?

Recent Perceptive Advisors portfolio additions include Imperative Care, Alto Neuroscience, Outlook Therapeutics, Solid Biosciences, Beam Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 224 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →